Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0801
    +0.0008 (+0.08%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2634
    +0.0012 (+0.10%)
     
  • USD/JPY

    151.2000
    -0.1720 (-0.11%)
     
  • Bitcoin USD

    70,100.62
    -596.70 (-0.84%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Vetr Urges Hold On Gilead After Kite Merger

On Friday, the Vetr crowd downgraded its rating on Gilead Sciences, Inc. (NASDAQ: GILD) from 3.5 stars (Buy), issued a week ago, to 3 stars (Hold). Crowd sentiment at the time of this writing was generally cautious, with 62 percent of Vetr user ratings bearish.

Earlier in the week, Gilead announced plans to acquire Kite Pharma Inc (NASDAQ: KITE). Since then, share price in the biotech has jumped by 13.5 percent to $83.75.

The announcement also garnered a fair amount of analyst attention. Argus' David Toung issued an upgrade on the stock from Hold to Buy on Thursday while, two days earlier, Robert Spingarn of Credit Suisse raised his price target on the stock from $79 to $85.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average price target on Gilead is up at $86.44, which is above the average analyst target price of $83.59. More than 2 percent of users are holding $GILD in their watch-lists.

Latest Ratings for GILD

Aug 2017

Argus

Upgrades

Hold

Buy

Aug 2017

Credit Suisse

Maintains

Outperform

Jul 2017

Redburn

Initiates Coverage On

Buy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

See more from Benzinga

© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement